OptimizeRx Overview
Valuation check: OPRX's P/E ratio is 32.64, above the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow32.64
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for OPRX is 32.64. That is above the Healthcare sector average of 25.9. Investors often review this figure alongside OptimizeRx's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, OPRX currently prints 32.64 for P/E ratio, while the sector average sits near 25.9. That is roughly 26.0% above the sector mean. Large gaps often invite a closer look at OptimizeRx's growth, margins, and balance sheet.
A P/E ratio of 32.64 for OptimizeRx is not 'good' or 'bad' on its own. Compare it with the peer average (25.9) and with OPRX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting OPRX's P/E ratio (32.64), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack OptimizeRx's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
